4 active trials 2 recruiting 3 Phase 3 2 disease areas 4 changes in 30 days
| Phase 2 | 1 | |
| Phase 3 | 3 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 3 | ||||
| NCT06081244 | NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk… | Triple Negative Breast Cancer | Recruiting | 2026-08-03 |
| NCT04055493 | Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in… | Breast Cancer Female | Active, Not Recruiting | 2026-05-11 |
| NCT04565054 | Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk… | Breast Cancer Female | Active, Not Recruiting | 2025-11-19 |
| Phase 2 | ||||
| NCT05704829 | NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus… | HER2-positive Early Breast Cancer | Recruiting | 2026-06-09 |
Breast Cancer (4) · Triple-Negative Breast Cancer (1)